Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL versus PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL versus PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE.
Labetalol vs PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Labetalol is a racemic mixture of four stereoisomers, each with distinct activity. It is a non-selective beta-adrenergic antagonist (blocking beta1 and beta2 receptors) and a selective alpha1-adrenergic antagonist. The alpha1 blockade causes vasodilation and reduces peripheral vascular resistance, while beta blockade reduces heart rate and myocardial contractility, leading to decreased blood pressure without significant reflex tachycardia.
Prilocaine is an amide local anesthetic that blocks sodium channels in neuronal cell membranes, inhibiting nerve impulse propagation. Epinephrine is a vasoconstrictor that prolongs local anesthetic action by reducing systemic absorption.
Oral: 200-1200 mg/day in 2 divided doses; initial 100 mg twice daily. IV: 20 mg bolus over 2 minutes, may repeat 40 mg at 10-minute intervals. Max cumulative dose: 300 mg.
Local infiltration: 0.5% to 2% solution with epinephrine 1:200,000; maximum dose 7 mg/kg prilocaine, not to exceed 600 mg. Nerve block: 1% to 2% solution; maximum dose 7 mg/kg. Repeat administration at intervals of at least 2 hours.
None Documented
None Documented
Clinical Note
moderateLabetalol + Digitoxin
"Labetalol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateLabetalol + Deslanoside
"Labetalol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateLabetalol + Acetyldigitoxin
"Labetalol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateLabetalol + Ouabain
"Labetalol may increase the bradycardic activities of Ouabain."
6-8 hours (terminal elimination half-life); may be prolonged in hepatic impairment, unchanged in renal impairment.
Prilocaine: terminal elimination half-life ~10–15 minutes (alpha phase) and 1.5–2 hours (beta phase); in hepatic impairment or methemoglobinemia, half-life prolonged (up to 3–4 hours). Epinephrine: short half-life ~2–3 minutes due to rapid uptake and metabolism.
Renal (55-60% as unchanged drug and metabolites); biliary/fecal (minor, approximately 5-10%); remainder metabolized in liver.
Renal excretion of metabolites (prilocaine metabolites: o-toluidine and 4-hydroxy-2-methylaniline, ~85%); epinephrine metabolites (metanephrine, vanillylmandelic acid) excreted renally; <5% excreted unchanged in urine; minimal biliary/fecal elimination (<2%).
Category A/B
Category A/B
Alpha/Beta-Blocker
Alpha/Beta Agonist